# Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

> **NCT00611468** · PHASE1 · COMPLETED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Solid Tumor

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00611468
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2011-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611468, "Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00611468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*